The stage of the tumor left after neoadjuvant chemotherapy for breast cancer - as determined by the revised American Joint Committee on Cancer (AJCC) tumor-node-metastasis staging system - is associated with both distant disease-free survival and overall survival, according to a new study.

In breast cancer, the extent of tumor left behind after neoadjuvant chemotherapy is an established intermediate endpoint for relapse and survival. In January 2003, the AJCC modified their tumor-node-metastasis staging system. To determine whether this new system is able to predict patient survival after neoadjuvant chemotherapy for breast cancer, Lisa A. Carey, M.D., of the University of North Carolina at Chapel Hill, and colleagues assessed the stage of the residual tumor in 132 patients with nonmetastatic breast cancer after they had undergone neoadjuvant chemotherapy. The patients were then followed for a median of 5 years.